FeesSafety
Pluang+

Artelo Biosciences unveils ART26.12, a novel non-opioid pain treatment, at IASP 2026 with promising early trial results.

Market News
26 Oct 2026, 14:55 WIB
GlobeNewsWire
View Source
Bullish
Artelo Biosciences unveils ART26.12, a novel non-opioid pain treatment, at IASP 2026 with promising early trial results.

Artelo Biosciences presented ART26.12, the first selective FABP5 inhibitor for pain, at the IASP 2026 World Congress on Pain. ART26.12 is a non-opioid, non-steroidal analgesic targeting chemotherapy-induced peripheral neuropathy and other chronic pain conditions, showing promising safety and efficacy in early human and nonclinical studies. The company plans to start a Phase 1 multiple ascending dose study in late 2026 to further evaluate ART26.12's potential as a safer alternative to opioids for pain management.

Artelo Biosciences' ART26.12 pain treatment is the subject, with Pluang's health sector market data providing context. Among 150 priced US health stocks on Pluang as of Oct 26, 2026 18:11 WIB, 82 rose and 35 fell. ERAS rose 1.84% to USD 14.65 with a typical hold time of 3 days, contrasting with ADPT and IMVT which fell 1.72% and 1.34% to USD 25.07 and USD 28.03, held typically for 37 and 17 days respectively.

More News

Smithfield Foods launches $250K scholarship for business students at Christopher Newport University

Smithfield Foods launches $250K scholarship for business students at Christopher Newport University

Smithfield Foods has created a $250,000 Future Leaders Scholarship program at Christopher Newport University to support eight incoming business students with $7,500 annual scholarships renewable for up to four years. The program aims to help local st...

Others
Bullish
1 hour ago
E-Power's Guizhou JV secures RMB 110M of RMB 200M capital raise, valuing it at RMB 2B post-money.

E-Power's Guizhou JV secures RMB 110M of RMB 200M capital raise, valuing it at RMB 2B post-money.

E-Power Inc.'s joint venture, Sunrise Guizhou, received RMB 110 million of a planned RMB 200 million capital increase, raising its registered capital and valuing the company at RMB 2 billion post-money. The funds will support business expansion, R&D,...

Company Fundamentals
Bullish
1 hour ago
Tallinna Sadam secures €50M loan to refinance bonds maturing in 2026, extending debt to 2031.

Tallinna Sadam secures €50M loan to refinance bonds maturing in 2026, extending debt to 2031.

AS Tallinna Sadam has signed a €50 million unsecured loan agreement with Swedbank, with a 5-year term and interest based on 3-month Euribor plus a margin. The loan will be fully drawn on October 26, 2026, and matures on October 26, 2031. This financi...

Company Fundamentals
Neutral
2 hours ago
AS Tallinna Sadam secures €50M loan to redeem bonds, supporting port operations and growth.

AS Tallinna Sadam secures €50M loan to redeem bonds, supporting port operations and growth.

AS Tallinna Sadam signed a €50 million unsecured loan agreement with AS Swedbank, maturing in five years with an interest rate based on 3-month Euribor plus margin. The loan, drawn on October 26, 2026, will be used to redeem bonds worth €50.4 million...

Company Fundamentals
Neutral
2 hours ago
Vita Coco and Homesick launch limited-edition candles inspired by Vita Coco Treats flavors

Vita Coco and Homesick launch limited-edition candles inspired by Vita Coco Treats flavors

Vita Coco, a leading coconut water brand, has partnered with Homesick to create a limited-edition candle collection inspired by Vita Coco Treats flavors: Strawberries & Creme and Frosted Lemonade. The candles capture the essence of these flavors thro...

Others
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App